Tackling antimicrobial resistance
Relevant BNF section: 5.1
Bacteria resistant to antibiotic therapy are becoming much more common and this has led to mounting concern in the UK and worldwide.1–4 Many pathogens are now 'multiresistant', that is, they are resistant to several classes of antimicrobial drug. Infection with such organisms may be particularly difficult to treat. In this article, we briefly discuss how resistance and multiresistance occur. We consider some of the important pathogens involved and the problems they pose in hospitals and the community. We discuss strategies for slowing the accumulation of antibiotic resistance and the implications for doctors treating patients with common infections.
This article has been cited by other articles:
-
Denamur, S., Van Bambeke, F., Mingeot-Leclercq, M.-P., Tulkens, P. M.
(2008). Apoptosis Induced by Aminoglycosides in LLC-PK1 Cells: Comparative Study of Neomycin, Gentamicin, Amikacin, and Isepamicin Using Electroporation. Antimicrob. Agents Chemother.
52: 2236-2238
[Abstract] [Full Text] -
(2008). Risks of extended-spectrum beta-lactamases. DTB
46: 21-24
[Abstract] [Full Text] -
Clements, H., Stephenson, T., Gabriel, V., Harrison, T., Millar, M., Smyth, A., Tong, W., Linton, C. J
(2000). Rationalised prescribing for community acquired pneumonia: a closed loop audit. Arch. Dis. Child.
83: 320-324
[Abstract] [Full Text]
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
